SK Bioscience Secures $230M Korea Growth Fund Backing for Pneumococcal Vaccine
Event summary
- SK Bioscience's board approved a KRW 300 billion ($230 million) financing plan backed by the Korea Growth Fund.
- The company is the first Korean novel drug and vaccine developer selected for the fund.
- Funds will support late-stage development of GBP410, a pneumococcal vaccine co-developed with Sanofi.
- Global Phase 3 trials for GBP410 are ongoing, with top-line results expected in late 2027.
- SK Bioscience relocated its headquarters to Songdo, Incheon, to integrate R&D and commercial functions.
The big picture
SK Bioscience's selection for the Korea Growth Fund marks a strategic shift in government support from manufacturing to R&D, signaling confidence in Korea's biotech innovation capabilities. The $230 million investment underscores the growing global competitiveness of Korean vaccine developers, particularly in late-stage clinical programs requiring significant capital. This funding could accelerate SK Bioscience's pivot from a regional player to a global contender in infectious disease prevention.
What we're watching
- Execution Risk
- Whether SK Bioscience can deliver top-line Phase 3 results for GBP410 on schedule in late 2027.
- Market Positioning
- How the $230 million investment will impact SK Bioscience's competitive standing in the global pneumococcal vaccine market.
- Government Strategy
- The pace at which Korea's Growth Fund continues to support biotech innovation beyond manufacturing infrastructure.
Related topics